Moderna (NASDAQ:MRNA) Price Target Cut to $25.00 by Analysts at Barclays

Moderna (NASDAQ:MRNA) had its target price reduced by equities research analysts at Barclays from $31.00 to $25.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Barclays‘s price objective suggests a potential upside of 5.42% from the stock’s current price.

MRNA has been the topic of a number of other research reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research note on Monday, October 20th. Morgan Stanley boosted their price objective on Moderna from $31.00 to $32.00 and gave the company an “equal weight” rating in a report on Friday, October 10th. UBS Group reduced their target price on Moderna from $70.00 to $40.00 and set a “buy” rating on the stock in a research note on Thursday, October 23rd. Evercore ISI set a $32.00 target price on Moderna in a research report on Friday, August 1st. Finally, Leerink Partners cut their price target on shares of Moderna from $18.00 to $15.00 and set an “underperform” rating on the stock in a report on Friday, August 22nd. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, twelve have given a Hold rating and five have assigned a Sell rating to the company. According to MarketBeat, Moderna currently has a consensus rating of “Hold” and an average price target of $36.43.

Moderna Stock Performance

Shares of MRNA stock traded down $0.62 on Friday, reaching $23.71. The stock had a trading volume of 5,211,627 shares, compared to its average volume of 10,953,079. Moderna has a 1 year low of $23.04 and a 1 year high of $50.90. The stock has a market cap of $9.26 billion, a P/E ratio of -3.15 and a beta of 2.02. The company has a 50 day simple moving average of $25.80 and a 200 day simple moving average of $27.13.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, November 6th. The company reported ($0.51) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.15) by $1.64. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The company had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $893.29 million. During the same quarter in the previous year, the company earned $0.03 EPS. Moderna’s revenue for the quarter was down 45.4% on a year-over-year basis. Moderna has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Moderna will post -9.61 earnings per share for the current fiscal year.

Institutional Trading of Moderna

Large investors have recently bought and sold shares of the stock. Parkside Financial Bank & Trust lifted its stake in shares of Moderna by 19.0% during the second quarter. Parkside Financial Bank & Trust now owns 2,347 shares of the company’s stock worth $65,000 after buying an additional 375 shares during the period. Probity Advisors Inc. lifted its position in Moderna by 2.6% during the 2nd quarter. Probity Advisors Inc. now owns 14,892 shares of the company’s stock worth $411,000 after acquiring an additional 377 shares during the period. Amalgamated Bank grew its stake in Moderna by 0.6% during the 2nd quarter. Amalgamated Bank now owns 65,458 shares of the company’s stock valued at $1,806,000 after purchasing an additional 408 shares during the last quarter. Rothschild Investment LLC increased its holdings in shares of Moderna by 94.1% in the second quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock valued at $25,000 after purchasing an additional 446 shares during the period. Finally, Blue Sky Capital Consultants Group Inc. lifted its holdings in shares of Moderna by 3.8% during the first quarter. Blue Sky Capital Consultants Group Inc. now owns 15,119 shares of the company’s stock worth $429,000 after purchasing an additional 556 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.